IGC Pharma Reports Third Quarter Financial Results
IGC Pharma has released its financial results for the third quarter ending September 30, 2026. The company reported quarterly revenue of $0.32 million, reflecting ongoing operations within its specific market segment. The company experienced an increase in its net loss, which reached approximately $2.046 million for the quarter, compared to a net loss of $1.821 million during the same period in the previous year. This resulted in a basic and diluted net loss per share of $0.02.
Read the full article at Seeking Alpha
Part of the story Novo Nordisk Reports Strong Third Quarter Results Driven by Oral Wegovy Growth (6 articles)